Effects of dofetilide and EGIS-7229, an antiarrhythmic agent possessing class III, IV, and IB activities, on myocardial refractoriness in hyperkalemia, hypokalemia, and during β-adrenergic activation in the rabbit papillary muscle in vitro

Journal of Pharmacological Sciences

Volumn 100, Issue 4, 2006, Pages 303-309

  Kovács, Anikó ^a   Szénási, Gábor ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Antiarrhythmic agent; Dofetilide; Effective refractory period; Hyperkalemia; Hypokalemia

Indexed keywords

5 CHLORO 4 [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYLAMINO] 3(2H) PYRIDAZINONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR; DOFETILIDE; ISOPRENALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC STIMULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; HEART MUSCLE REFRACTORY PERIOD; HEART PAPILLARY MUSCLE; HEART RIGHT VENTRICLE; HEART VENTRICLE PACING; HYPERKALEMIA; HYPOKALEMIA; IN VITRO STUDY; MALE; NONHUMAN; RABBIT; STIMULATION;

EID: 33645873885     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0051009     Document Type: Article

References (24)

1. Hondeghem L, Snyders D. Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation. 1990;81:686-690.
2. 2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome. J Physiol. 2002;543:615-631.
3. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002;25:263-286.
4. Kr. Implications for torsade de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
5. Gjini V, Korth M, Schreieck J, Weyerbrock S, Schömig A, Schmitt C. Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. J Cardiovasc Pharmacol. 1996;28:314-320.
6. Marschang, H, Beyer T, Karolyi L, Kübler W, Brachmann J. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle. Cardiovasc Drugs Ther. 1998;12:573-583.
7. Marschang H, Schöls W, Karolyi L, Beyer T, Kübler W, Brachmann J. Differential effects of d-sotalol on subendocardial Purkinje myocytes isolated from normal or 10 to 14 days postinfarction canine hearts: role of extracellular potassium concentration. J Cardiovasc Pharmacol. 1998;32:274-283.
8. Yang T, Tande PM, Lathrop DA, Refsum H. Effects of altered extracellular potassium and pacing cycle length on class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle. Cardiovasc Drugs Ther. 1992;6:429-436.
9. Sanguinetti MC, Jurkiewitz NK, Scott A, Siegl PK. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action. Circ Res. 1991;68:77-84.
10. Sager PT, Follmer C, Uppal P, Pruitt C, Godfrey R. The effects of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans. Circulation. 1994;90:1811-1819.
11. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
12. Martin C, Palomo M, McMahon E. Comparison of bidisomide, flecainide and dofetilide on action potential duration in isolated canine atria: effect of isoproterenol. J Pharmacol Exp Ther. 1996;278:154-162.
13. Nánási P, Szénási G. EGIS-7229: A new potent antiarrhythmic candidate with combined mode of action. Cardiovasc Drug Rev. 1997;15:314-334.
14. Kovács A, Gyönös I, Magyar J, Bányász T, Nánási PP, Spedding M, et al. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro. J Cardiovasc Pharmacol. 2001;37:78-88.
15. Pankucsi C, Bányász T, Magyar J, Gyönös I, Kovács A, Varró A, et al. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:398-405.
16. + activities and resting membrane potential in sheep cardiac purkinje strands. Circ Res. 1980;47:692-700.
17. Janse M, Wit A. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989;69:1049-1169.
18. Pacini D, Boachie-Ansah G, Kane K. Modification by hypoxia, hyperkalemia and acidosis of the cardiac electrophysiological effects of a range of antiarrhythmic drugs. Br J Pharmacol. 1992;107:665-670.
19. Magyar J, Bányász T, Fülöp L, Szentandrassy N, Körtvély Á, et al. Effects of the antiarrhythmic agent, EGIS-7229 (S 21407) on calcium and potassium currents in canine ventricular cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:604-611.
20. Wolk R, Kane KA, Cobbe SM, Hicks MN. Apex-to-base dispersion of refractoriness underlies the proarrhythmic effect of hypokalaemia/hypomagnesaemia in the rabbit heart. J Electrocardiol. 2002;35:245-252.
21. 2 (ZP123): in vivo and in vitro studies. J Pharmacol Exp Ther. 2003;306:1191-1199.
22. Reiter MJ, Mann DE, Williams GR. Interaction of hypokalemia and ventricular dilatation in isolated rabbit hearts. Am J Physiol. 1993;265:H1544-H1550.
23. Cobbe SM, Manley BS, Alexopoulos D. The influence of acute myocardial ischemia on the class III antiarrhythmic action of sotalol. Cardiovasc Res. 1985;19:661-667.
24. Kr blockers dofetilide, d-sotalol, E-4031 and MK-499. J Cardiovasc Pharmacol. 1994;24:199-208.